DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions

• Published in: Pharmacology & therapeutics (Oxford) 2020-11, Vol.215, p.107617-107617, Article 107617
• Main Authors: Medová, Michaela, Medo, Matúš, Hovhannisyan, Lusine, Muñoz-Maldonado, Carmen, Aebersold, Daniel M., Zimmer, Yitzhak
• Format: Article
• Language: English
• Subjects: Cancer; Clinical trials; DNA-PK; Non-homologous end-joining; Targeting
• ISSN: 0163-7258; 1879-016X
• DOI: 10.1016/j.pharmthera.2020.107617

The DNA-PK holoenzyme is a fundamental element of the DNA damage response machinery (DDR), which is responsible for cellular genomic stability. Consequently, and predictably, over the last decades since its identification and characterization, numerous pre-clinical and clinical studies reported observations correlating aberrant DNA-PK status and activity with cancer onset, progression and responses to therapeutic modalities. Notably, various studies have established in recent years the role of DNA-PK outside the DDR network, corroborating its role as a pleiotropic complex involved in transcriptional programs that operate biologic processes as epithelial to mesenchymal transition (EMT), hypoxia, metabolism, nuclear receptors signaling and inflammatory responses. In particular tumor entities as prostate cancer, immense research efforts assisted mapping and describing the overall signaling networks regulated by DNA-PK that control metastasis and tumor progression. Correspondingly, DNA-PK emerges as an obvious therapeutic target in cancer and data pertaining to various pharmacological approaches have been published, largely in context of combination with DNA-damaging agents (DDAs) that act by inflicting DNA double strand breaks (DSBs). Currently, new generation inhibitors are tested in clinical trials. Several excellent reviews have been published in recent years covering the biology of DNA-PK and its role in cancer. In the current article we are aiming to systematically describe the main findings on DNA-PK signaling in major cancer types, focusing on both preclinical and clinical reports and present a detailed current status of the DNA-PK inhibitors repertoire.